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1. Introduction 
Natural immunity against malaria is acquired after repeated infections for an extended 
period of time resulting in a state of immunological non-responsiveness against the malaria 
parasite. This state ultimately prevents the onset of severe disease such as cerebral malaria 
thereby reducing the risk of death from malaria. Individuals with acquired natural 
immunity to malaria still harbor parasites (albeit in low densities) in the blood, and 
therefore natural immunity against malaria is not sterile. For this reason, natural immunity 
to malaria cannot be compared to immunity achieved against other diseases where the 
immune response neutralizes and eliminates the pathogen. The second hallmark of natural 
immunity to malaria is that protection wanes once a “protected” individual leaves the 
malaria-endemic area indicating that protection depends on continued antigen exposure. 
Immunity to malaria is stage- and species-specific and distinct immune mechanisms confer 
protection against the different developmental stages of the parasite. In the case of blood 
stage infection, passive transfer experiments with purified human immunoglobulins 
derived from immune individuals living in malaria-endemic areas have demonstrated that 
antibodies can mediate protection (Cohen et al., 1961; Butcher et al., 1970; Bouharoun-
Tayoun et al., 1990). Mechanistic studies revealed that the effect of blood stage-specific 
antibodies on the asexual erythrocytic parasite depends on their antigen-specificity; 
antibodies can bind to merozoites, opsonize and target them towards phagocytic cells of the 
host (Groux and Gysin, 1990), or prevent invasion of new erythrocytes (Perkins, 1991). Once 
infected, antibodies against asexual blood stage antigens such as Pf332 or MSP-1 inhibit the 
intra-erythrocytic development of Plasmodium falciparum (Ahlborg et al., 1996; Siddique et 
al., 1998; Bergmann-Leitner et al., 2009). Antibodies directed to antigens expressed by sexual 
erythrocytic stages (gametocytes) have been shown to prevent transmission of malaria by 
blocking either the infection of the mosquito or the development in the mosquito (Lavazec 
and Bourqouin, 2008). As will be outlined in this chapter, it becomes increasingly clear that a 
blood stage vaccine may never be able to induce sterile protection, but can prevent 
mortality. Why bother developing blood stage vaccines? Extensive studies characterizing 
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the leading pre-erythrocytic vaccine RTS,S have shown approximately 40% sterile protection 
of vaccinated US individuals (Kester et al., 2007). Protection in the field is restricted to 
reduced mortality and morbidity and requires vaccination of young children that have 
continued exposure to the parasite. Under these circumstances, partial protection (when 
defined as time to first clinical episode) was approx 30% (Sacarlal et al., 2009). The limited 
efficacy of pre-erythrocytic vaccines appears to be the result of the fact that even a few 
sporozoites which escape the vaccine-induced immune response are still capable of 
establishing full blown blood stage infection. Combining a pre-erythrocytic vaccine such as 
RTS,S with a blood stage vaccine would assure that individuals, who did not develop sterile 
immunity (sterile immunity has never been achieved in field trials) would have a reduced 
risk of dying as a result of the added blood stage component.  
This chapter will highlight the major readout methods that are currently used to gauge the 
efficacy of blood stage vaccines. In the absence of ‘protection’ models, the study of blood 
stage vaccines requires the development of in vitro assays that predict vaccine efficacy. In 
the absence of a definitive correlate of protection, the predictive value of these assays still 
awaits validation. Various target antigens for vaccine development will be highlighted with 
a special focus on the Merozoite Surface Protein (MSP)-1. Lastly, we will discuss modes of 
action of immune effector mechanisms against blood stage parasites and provide a preview 
of next-generation malaria vaccines. 
2. Methodological tools to study anti-parasite activities mediated by 
Plasmodium-specific antibodies 
The ability to culture blood stage parasites of P. falciparum has greatly assisted in our 
understanding of events associated with maturation of the intra-erythrocytic parasite 
(Trager and Jensen, 1976; Haynes and Moch, 2002; Haynes et al., 2002). This is underscored 
by the lack of knowledge for other Plasmodium species that have not been successfully 
established in culture. Once the liver schizonts have reached maturity, the hepatocyte 
membrane dissolves and the merosome, i.e., the parasitophorous vacuole which resembles a 
bag containing infectious merozoites, is released from the liver destined for the lung 
capillaries where infection of erythrocytes occurs (Baer et al., 2007). The erythrocytic life 
cycle of P. falciparum blood stage parasites ranges from 38-48 hrs. During the first 24 hrs the 
parasite has a ring-like morphology (ring stage parasite) which subsequently develops into a 
trophozoite that is clearly distinguishable by the increasing amount of DNA and cytoplasm. 
Further maturation of the parasite into the schizont stage is marked by DNA segmentation 
resulting in individual nuclei. Additionally, schizonts have increasing amounts of digested 
hemoglobin (aka, malaria pigment or hemozoin). The schizonts rupture after first dissolving 
the parasitophorous vacuole and then the erythrocyte membrane, thus releasing 16-32 
infectious merozoites per new infected erythrocyte (Cowman and Crabb, 2006). This event 
typically occurs in post capillary venules where the flow rate of the blood is low thereby 
favoring the rapid invasion of erythrocytes. Free merozoites have a relatively short lifespan 
and thus it is thought that the invasion event occurs quickly (within 5 minutes). This poses a 
significant challenge for effector antibodies which have to engage the parasite during this 
brief period of vulnerability and to block the interactions between host cells and merozoites. 
Successful active or passive immunotherapy requires providing an ample supply of antigen-
specific, high-affinity antibodies capable of blocking a ‘tsunami’ of parasites every 38-48 
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hours. Whether this will be achievable to prevent morbidity or whether blood stage vaccine-
induced antibodies will only be able to prevent severe disease and mortality is currently the 
focus of erythrocytic vaccines. Ideally, in vitro methods and/or preclinical models would 
assist in the down-selection of vaccine candidates. However, currently there is no preclinical 
model that adequately simulates human malaria. In contrast, there are several in vitro 
methods that have been used for analyzing functional antibodies against blood stage 
parasites in vitro. The following methods have been employed extensively in the evaluation 
of blood stage vaccines and we outline the advantages and drawbacks of the various 
methods as well as their predictive value.  
2.1 Functional assays capturing the biological activity of blood stage, parasite-
specific antibodies 
Various methods have been developed that allow the measurement of the biological 
functionality displayed by either the antibodies themselves (growth inhibition assays (GIA) 
and invasion inhibition assays (IIA)) or antibodies in collaboration with immune cells 
expressing Fc-receptors (receptors that naturally bind certain immunoglobulin isotypes in 
order to eliminate antigens bound by antibodies). Antibodies bind their specific pathogen 
and form “immune complexes”. Depending on the class and isotype of the antibody in the 
immune complex, this interaction leads to different outcomes: (1) the immune complex 
activates the complement system, i.e. complement fixation (which ultimately results in the 
lysis of the attached pathogen) or (2) the immune complex binds to Fc-receptors, i.e. 
opsonization (mediating uptake of the bound pathogen by the immune cells) or (3) antibody 
binds to the antigen and inactivates (neutralizes) the pathogen and thus prevents infection. 
The functional analysis of anti-blood stage antibodies, especially when obtained from 
individuals in endemic areas, is complicated by the presence of toxic factors or lipids in sera 
or plasma (such as anti-malarial drugs and anti-coagulants, or oxidized lipids due to long or 
inadequate sample storage). Eliminating nonspecific toxicities requires purification of the 
antibodies from serum or plasma using either bulk enrichment techniques (such as 
precipitation with ammonium sulfate and caprylic acid) or immunoglobulin purification 
methods (e.g., the use of Protein A, G , L-columns). It should be noted that most anti-malarial 
drugs can be removed by simply dialyzing the samples (Sy et al., 1990; Persson et al., 2006) 
which allows the testing of samples where only small volumes are available as is often the case 
for pediatric specimen. When comparing various methods in regards to yield, purity, integrity 
and retention of functional activity of recovered antibodies, we found that some methods lead 
to the selective enrichment of certain isotypes or in some cases fairly unstable immunoglobulin 
preparations (Bergmann-Leitner et al., 2008b). Also, not all purification methods perform 
equally well when purifying immunoglobulins from different species. The choice of 
purification method greatly influences the results obtained in the functional assay and can lead 
to significant artifacts. 
2.1.1 Microscopic analysis  
Microscopic evaluation of blood smears stained with Giemsa is the classic method for 
detecting parasitized erythrocytes (pRBC) and remains the gold standard in clinical trials. It 
is also used for studying the effect of antibodies on the morphology of the intra-erythrocytic 
parasite. To detect parasitemia in the blood, thick film-smears are prepared and 100 
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microscopic fields are screened for the presence of parasites at a 1000x magnification. For 
quantitation, 200 leukocytes and all pRBC in the respective fields of a thin film-smear are 
counted. If nine or less pRBC per 200 leukocytes are detected the quantitation is extended 
to 500 leukocytes. The equipment is readily available in all clinical labs and is fairly cheap. 
However, since the analysis is done by humans, it is essential that it is performed in a 
double-blinded fashion to avoid introduction of bias and subjectivity. Moreover, the 
microscopists have to be highly trained and experienced in slide reading in order to 
reliably identify malaria parasites in thick and thin film blood smears. The expertise of 
microscopists has long been recognized as the key issue for evaluating vaccine and 
malarial drug trials as quantifying parasitemia of malaria infected individuals commonly 
defines a study’s primary endpoint. Furthermore, manual analysis, i.e. individual slide 
reading, is also rather slow and therefore not suitable for high-throughput screening. The 
microscopic analysis permits the quantification of parasitemia, but cannot objectively 
characterize changes in morphology which would indicate developmental growth 
inhibition or retardation. 
2.1.2 Flow cytometric analysis 
Flow cytometry is an ideal methodology for the automated and objective analysis of large 
numbers of cells. It provides information about the number of positively stained cells as well 
as the intensity of staining (Shapiro, 2004). Staining of mature human erythrocytes with 
DNA dyes allows for the detection of Plasmodium infection as these host cells are devoid of 
DNA unless parasites are present. This analysis reveals both the percentage parasitemia in 
the culture (% DNA containing cells) as well as the intracellular DNA content which is 
indicative of the parasite’s maturation stages within the infected cells. Various DNA dyes 
have been reported to be useful for the detection and quantification of pRBC (reviewed in 
(Grimberg, 2011)). We have compared several DNA dyes side-by-side (i.e., Syto-16, 
SybrGreen and Hydroethidine) in order to determine their usefulness in measuring invasion 
and growth inhibition of anti-blood stage antibodies. Using standard DNA binding dyes 
such as Syto-16 (Brand et al., 2003) and SybrGreen allows only the quantification of pRBC in 
culture and does not assess the viability of the intra-erythrocytic parasite (Green et al., 1981; 
Pang et al., 1999; Tebo et al., 2001; Haynes and Moch, 2002). If invasion occurs but the 
parasite fails to thrive, then the infected cell is detectable. Thus this approach measures only 
invasion inhibition since antibodies that block invasion result in either low or no 
parasitemia. In order to assess actual developmental growth inhibition, a different strategy 
has to be employed:  
(1) Measurement of the DNA content of the pRBC as a correlate of the maturation stage of 
the parasite (Figure 1). A prerequisite for this approach is the tight synchronization of the 
parasites – either through repeated Percoll/Sorbitol purification or growth in temperature-
cycling incubators - prior to setting up the experiment as the analysis requires setting strict 
cut-off values (see Fig. 1) for the different maturation stages of the parasite 
(ring/trophozoite/schizont). Such cut-off values have to be established for every parasite 
clone and isolate and have to be revised whenever culture conditions (new batch of serum/ 
culture media) change. Failure to control for these changes and the different growth kinetics 
of isolates and clones results in inaccurate estimates of parasite growth and yields 
uninterpretable results.  
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(2) Use of viability DNA stains such as hydroethidine (HE) (van der Heyde et al., 1995). HE-
staining depends on the intracellular conversion of HE into ethidium by parasitic NADPH 
oxidase and has been described in various protozoan systems including malaria to be a 
reliable metabolic indicator of parasite viability (Wyatt et al., 1991; van der Heyde et al., 
1995). The host erythrocytes' enzymatic activity is not sufficient to convert the dye and, 
therefore, host cells do not introduce artifacts into this analysis. 
 
Fig. 1. DNA content of blood cultures infected with P. falciparum in the presence of control 
(malaria-naïve, not growth inhibitory) serum (Panel A) or immune serum (Panel B) 
determined by flow cytometric analysis. X-axis = Mean fluorescence intensity of Syto-16 
DNA staining, Y-axis = arbitrary unit for cell number. Brackets under X-axis indicate the 
DNA content of uninfected erythrocytes (RBC), ring stage parasites (RS), multiply infected 
ring stage parasites (MI-RS) and trophozoites (Tz) and schizont stage parasites (Sz). Marker 
M1 captures young pRBC and M2 mature pRBC and the changes of the proportion have 
been used to calculate growth inhibition. Panel A serves as reference for healthy, un-
impaired parasite growth. Panel B indicates growth retardation as there is a higher 
prevalence of ring and trophozoite stage parasites compared to the control serum. The 
difference between the area under the curve for M1 of the test culture and the control 
culture is used to report the percentage of growth inhibition. 
2.1.3 Measurement of invasion inhibition by using transgenic parasites 
In an attempt to identify the contribution of MSP-1 mediated invasion inhibition, O’Donnell 
et al. (O'Donnell et al., 2001) developed a P. falciparum D10 clone (MAD 20 allele) transgenic 
in the MSP-1p19 portion where the wildtype sequence was replaced by the p19 of P. 
chabaudi. Testing the inhibitory activity of antibodies against the parental D10 compared to 
the transgenic parasites identifies the contribution of P.falciparum MSP-1 mediated parasite 
inhibition. Other transgenic parasites have been developed that express the green 
fluorescence protein to facilitate the detection of the parasites within erythrocytes 
(O'Donnell et al., 2000). This approach eliminates the need for intracellular DNA staining of 
pRBCs. Using these parasites requires maintaining an additional parasite strain in the 
laboratory, which adds cost and labor, but it greatly facilitates the analysis because no 
additional manipulation of the cultures, i.e., DNA staining, is required to perform the 
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analysis. The analysis would yield similar results as staining with a general DNA dye such 
as SybrGreen, which allows accurate detection of invasion inhibition while the quantitation 
of growth inhibition is challenging as outlined above. 
2.1.4 Measurement of the metabolic activity of the intra-erythrocytic parasite 
An alternative to quantifying either parasitized cells or the DNA content of infected 
erythrocytes is the measurement of enzymatic activity. The following approaches have been 
previously described: (1) the quantification of 3H-hypoxanthine incorporation into newly 
synthesized DNA (Bungener and Nielsen, 1968; Rahman, 1997), (2) the conversion of 
hydroethidine to ethidium (Wyatt et al., 1991; van der Heyde et al., 1995), and (3) 
detection/measurement of the parasite-derived lactate dehydrogenase (pLDH) (Makler and 
Hinrichs, 1993; Prudhomme and Sherman, 1999). Measuring the metabolic activity allows 
for the detection of parasitized erythrocytes that are viable and metabolically active thus 
enabling the quantitation of growth inhibition. It should be pointed out that multiple LDH-
substrates have been described in the literature for Plasmodium ssp. There are, however, 
qualitative differences between these substrates that will affect the sensitivity and the signal-
to-noise ratio. The protocol developed at NIAID/NIH (Kennedy et al., 2002) has 
demonstrated robustness, reproducibility and specificity (Corran PH, manuscript in 
preparation). This basic protocol was optimized in our laboratory to accommodate small 
sample volumes (< 50 µl) and high throughput screening utilizing 384 well plates and assay 
volumes of ≤ 20 µl (Bergmann-Leitner et al., 2008a).  
2.2 The quest for the most sensitive method for identifying anti-parasite activity of 
anti-malarial antibodies 
We have compared four methods in an attempt to identify the most sensitive method 
capable of measuring an array of functional activities displayed by immune antibodies, 
namely: (1) GIEMSA-staining of blood smears (with visual detection); (2) flow cytometric 
analysis using either a standard DNA binding dye (Syto-16) or (3) hydroethidine; and (4) 
pLDH detection using a substrate specific for the parasitic enzyme LDH (Bergmann-Leitner 
et al., 2006). The model system to evaluate anti-parasite activities was based on the use of 
immune sera specific for either AMA-1 (Kennedy et al., 2002) or MSP-1p42 (Angov et al., 
2003; Darko et al., 2005) and previously established P. falciparum parasite clones (namely 
3D7 and FVO). While staining with Giemsa revealed antibody-induced morphological 
changes in parasite development after exposure to immune serum, directly correlating these 
changes with parasite viability and thus efficacy of the antibodies is limited due to the 
subjective nature of the readout method. The DNA dye Syto16 readily permeates 
membranes of both viable and non-viable cells and thus cannot be used to determine the 
parasites’ viability since any erythrocyte with DNA content will equally be identified as an 
“infected cell”, thus under-estimating the inhibition. Growth inhibition (viability), however, 
can be determined by either flow cytometric analysis of parasites whose DNA was stained 
with HE or by measuring the enzymatic activity of pLDH. The conclusion from this 
comparative study was that the mode of action of antibodies directed against malaria blood 
stage antigens depends on not only the target antigen but also on the parasite strain. In cases 
where antibodies primarily mediated invasion inhibition, such as anti-AMA-1 specific 
antibodies (Triglia et al., 2000; Healer et al., 2004), all four methods yielded similar results. 
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However, antibodies directed against MSP-1p42 preferentially inhibited invasion or 
inhibited either parasite growth and development, depending on the parasite test strain. 
MSP-1 specific antibodies acted on the FVO parasite clone mainly by inhibiting invasion. In 
contrast, the same antibodies mediated invasion- and growth inhibition in the case of 3D7 
parasites (the exact mechanisms involved in this anti-parasite activity will be discussed in 
section 5). This study demonstrated that readout methods, which can distinguish between 
invasion inhibition and growth inhibition of the intra-erythrocytic parasite must be 
employed in order to comprehensively define the antibodies’ mechanism of action.  
In an effort to increase the sensitivity of the readout methods used to assess the anti-parasite 
activity through DNA dyes and flow cytometric analysis, multi-cycle experiments have been 
evaluated (Haynes et al., 2002; Persson et al., 2006), (Bergmann-Leitner, unpublished 
observations). To this end, cultures were not limited to the length of a single life cycle (40-48 
hours duration), but allowed to continue for at least another cycle (72-96 hours duration). 
Several caveats are associated with this experimental setup: (1) The starting parasitemia of 
the culture has to be adjusted for each isolate/clone to assure that the parasites will not 
overgrow after the completion of the first cycle. This would result in the depletion of 
nutrients and the exhausted culture conditions would result in an overestimation of growth 
inhibition. One remedy has been to feed the cultures once or repeatedly. This can, however, 
pose yet another challenge as the exchange of media dilutes the antibodies and without 
knowing at which stage they will take effect, this manipulation could reduce their biological 
activity. Replenishing the antibodies when changing the media may lead to an 
overestimation of the biological effect in cases where the antibodies have already bound to 
the surface of the pRBC or entered the parasitophorous vacuole. Therefore, adding more 
antibody artificially increases the total antibody concentration; (2) Outgasing of cultures (i.e., 
change in the ratio of CO2 and O2 in the atmosphere due to exposure to regular air) during 
the feeding process, can result in reduced invasion or slowed growth; (3) Interrupting 
invasion events when feeding occurs very closely to the time of schizont rupture. Estimating 
a safe time frame may be challenging because antibodies may slow the growth of the 
parasite, but not inhibit it and the growth inhibitory effect would be amplified; and (4) 
Controlling for proper starting parasitemia and modifying feeding times still leads to 
reduced multiplication rates in static cultures. Using suspension cultures for larger culture 
vessels such as 24-well plates and culture flasks yielded similar multiplication rates of the 
parasites during the second cycle compared to the first cycle (when feeding was also 
performed). It should be noted, however, that we have been unable to replicate the 
beneficial effect of suspension cultures when scaling down the assay format to 96 well and 
48 well plates (Bergmann-Leitner, unpublished observation).  
2.3 Functional assays to evaluate antibody dependent cellular cytotoxicity (ADCC) 
Early studies have shown that antibodies per se may not be sufficient to block the blood 
stage parasites (Bouharoun-Tayoun et al., 1990; Ouevray et al., 1994) and a cellular 
component is involved in the antibody-mediated anti-parasitic effect. Compared to classic 
antibody-dependent cellular cytotoxicity (ADCC), the postulated antibody-dependent 
cellular inhibition (ADCI) is mediated only by blood monocytes (not macrophages, 
polymorphonuclear neutrophils (PMN), lymphocytes, platelets) and primarily by cytophilic 
immunoglobulin classes (particularly IgG3) that target merozoite surface antigens 
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(Bouharoun-Tayoun et al., 1995; Tebo et al., 2001). The activation of monocytes through 
FcγRII triggers the release of soluble TNF-α that in turn blocks the development of adjacent 
intra-erythrocytic parasites (Bouharoun-Tayoun et al., 1995). Furthermore, a role of FcγRI in 
contributing to clinical malaria has been suggested based on the functional properties of 
recombinant human antibodies derived from immune Gambian adults (McIntosh et al., 
2007). These antibodies were tested in mice transgenic for human Fc-receptors challenged 
with transgenic rodent malaria parasites (expressing PfMSP-1p19) in an effort to evaluate 
the role of antibodies in protection. Another study demonstrated that the activation of 
monocytic cells requires two distinct Fcγ receptors (FcγRII and FcγRIII) simultaneously 
engaged by a least two cytophilic IgG molecules, which are part of the same immune 
complexes (Jafarshad et al., 2007). Finally, the concept of the contribution of Fc receptors in 
natural immunity is supported by epidemiological studies (Shi et al., 2001; Israelsson et al., 
2008; Leoratti et al., 2008). 
We conclude from these studies that ADCI as an anti-parasite defense mechanism depends 
on the target antigen, a concept with significant implications for vaccine development 
(revisited below in section 4). Experiments measuring the ADCI activity of anti-blood stage 
antibodies are set up in principle as described for growth/invasion inhibition assays 
(above): parasite cultures are established at a defined percentage of parasitemia in the 
presence or absence of immune antibodies and – in addition - in the presence of monocytic 
cells. Readout methods used are the same as for the standard “growth inhibition” assays as 
described earlier (our lab prefers the pLDH assay for this purpose). Note that the source and 
quality of the monocytic cells will greatly influence the results obtained in these 
experiments: (1) freshly isolated PBMC (plastic adherence vs. CD14 MACS separated cells 
vs. monocytic tumor cell lines); (2) resting vs. cytokine activated cells; or (3) inter-donor 
variations. When optimizing the ADCI protocol, it is important that the in vitro conditions 
including the cell types of phagocytes used simulate the in vivo setting as closely as possible 
in order to reproduce the conditions in the malaria infected host. Using cancer cells such as 
the monocytic tumor cell line THP-1 may not adequately mimic the effector population 
found in the patient. This is underscored by recent findings that infection and acute malaria 
can drastically change the phenotype of monocytic subpopulations (Chimma et al., 2009). 
This includes changes in chemokine receptors as well as functional properties. This was 
evidenced as monocytic cells derived from patients during an acute malaria infection were 
superior over the monocytes derived from healthy donor individuals. However, other 
studies have described significant impairments of monocyte functions due to malaria 
infection, such as their ability to phagocytize (Leitner and Krzych, 1997). This underscores 
that there is more to monocytic cells than just the expression of Fc-receptors and that these 
observations warrant the characterization of effector cells used for in vitro assays in an effort 
to minimize in vitro artifacts. 
To this end, we tested various methods for generating activated monocytic cells in vitro and 
found that the purification of monocytes with magnetic bead labeled anti-CD14 monoclonal 
antibody resulted in higher and more reproducible ADCI-activities as compared to cells that 
were isolated by plastic adherence. Moreover, pre-activating the isolated cells overnight 
with 300 U/ml IFN-γ reduced the inter-assay variability. Pre-activation also decreased the 
variability observed between different blood donors consistent with the concept that the 
stimulation “normalizes” the activation state of the cells (data not published).  
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What role does the parasite isolate or clone play when measuring ADCI activity? Using a 
sample from an individual from a malaria-endemic area (Lyon et al., 1997) we were able to 
detect a differential contribution of ADCI in the growth-inhibition of two P. falciparum 
clones: various amounts of serum in the assay in the presence or absence of monocytes were 
tested against the 3D7 and FVO parasite clones (Figure 2). The main difference in the clones 
is the fact that they represent the two distinct MSP-1 alleles (the MAD20 and the Wellcome 
K1 allele, respectively) and they have also been described as invading either through sialic 
acid independent (3D7) or dependent (FVO) pathways. The inhibitory activity of serum 
against 3D7 parasites was not increased by the presence of monocytes while the inhibition of 
FVO parasites could be amplified by adding monocytes (data not published). This 
synergistic effect of antibodies and monocytes became apparent when limiting the amount 
of serum in the assay. More studies are needed to determine the underlying mechanism for 
this differential effect as this may be a matter of antibody fine specificity (discussed in 
section 5).  
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Fig. 2. Effect of inhibitory antibodies and antibody-dependent cellular inhibition on growth 
of 3D7 (left Panel) and FVO (right Panel) parasite clones. X-axis indicates percentage of 
human malaria-immune serum in the culture; y-axis shows the % growth inhibition 
measured by quantifying pLDH. White bars = growth inhibition induced by serum only, 
black bars = growth inhibition induced by serum and CD14+ IFN-γ activated monocytes. 
Data expressed as mean % growth inhibition, error bars indicate SD. 
3. Anti-parasite activities in sera from individuals living in malaria-endemic 
areas 
Protection against malaria mediated by antibodies recognizing the erythrocytic parasite or 
the parasitized erythrocyte is mediated by several distinct mechanisms: (1) Binding of the 
antibody to the surface of merozoites can interfere with the invasion of new erythrocytes 
and opsonize the merozoite, which results in complement activation and/or phagocytosis; 
(2) Binding to the merozoite may not suffice to block invasion, but antibodies carried into 
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the infected RBC by the merozoite can result in growth inhibition; (3) Binding to pRBC can 
prevent sequestration, thus exposing the pRBC to conditions that are unfavorable for 
development, which may lead to increased clearance of pRBC by the spleen; and (4) Binding 
to pRBC can interfere with rosetting, a prerequisite for invasion. Studying the invasion of 
erythrocytes by merozoites has resulted in the identification of various invasion pathways, 
which the parasite can utilize. These pathways can be categorized broadly into: (1) sialic 
acid dependent and (2) sialic acid independent pathways. Field studies of the anti-parasite 
activity in sera from individuals with acquired natural immunity have shown that one of the 
earliest mechanisms to block blood stage parasites is to develop antibodies that interfere 
with the sialic acid dependent invasion (Baum et al., 2003; Nery et al., 2006; Persson et al., 
2008). Antibodies obtained from sera of young African children are more likely to block 
sialic acid dependent pathways while the ability to block sialic acid independent pathways 
is acquired after years of exposure to the parasite and with age. Antibodies capable of 
inhibiting rosetting can mediate protection, which reduces the risk of cerebral malaria 
(Vigan-Womas et al., 2010). Nevertheless, the actual role of antibodies in protecting against 
disease in the field remains controversial. While they may reduce the parasite load of 
individuals living in endemic areas, they do not mediate sterile protection or total 
suppression of parasites in the blood (Genton et al., 2002). Recently, an apical merozoite 
antigen (AMA)-1 based vaccine that induces high antibody titers, and high GIA responses in 
vitro in human vaccinees (Ellis et al., 2009) was evaluated for its protective effect in a blood 
challenge. To this end, the vaccinees were immunized and then challenged with blood 
infected with the 3D7 parasite clone. While the vaccine was able to reduce the multiplication 
rate in vivo, it was unable to mediate complete elimination of the parasites after a blood 
challenge (Duncan et al., 2011). This may indicate that either a single antigen such as AMA-1 
or blood-stage antigens in general may be able to alleviate the morbidity associated with 
disease (as seen in the case of natural immunity), but may not be able to induce complete 
protection against disease. 
Longitudinal studies in hyper-endemic malaria transmission areas have revealed factors 
related to the development (or lack thereof) of malaria-specific antibodies. Due to 
overlapping malaria infections in high transmission areas, where infections can occur 
frequently or even daily, it is difficult to study immune responses elicited by and 
maintained after a discrete infection. Studies in high transmission areas have a limited 
ability to consider age because participants suffer many unrelated infections during their 
first 5 years of life, including viral, bacterial and other parasitic diseases. One example is 
nematode infections, which are quite common in malaria-endemic areas and predispose the 
host to Th2-type immune responses. Exposure to malaria is an important potential 
confounder in immune-epidemiological studies. Therefore, the inadequate measurement 
and adjustment for differences in exposure may lead to the underestimation of the strength 
of associations between immunological variables and malaria incidence (Kinyanjui et al., 
2009). The strongest evidence that antibodies are important mediators of naturally acquired 
immunity is from passive transfer experiments of antibody from immune adults used to 
treat children with severe P. falciparum malaria (Cohen et al., 1961; McGregor and 
Carrington, 1963; Bouharoun-Tayoun et al., 1990). IgG and IgM antibodies present in sera of 
malaria-exposed individuals recognize and bind directly to trophozoites or schizonts. 
Neutralization and agglutination of merozoites and pRBC by these antibodies are reported 
as possible protective mechanisms during Plasmodium infection (Cohen and Butcher, 1971). 
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IgM antibodies are characterized by lower affinity for antigen compared to their IgG 
counterparts because little or no somatic hypermutation and clonal selection has occurred. 
IgM antibodies form pentamers to compensate for the lower affinity, which results in a 
higher overall avidity due to increased number of binding sites. Evidence for a protective 
role of IgM against malaria infection (Wahlgren et al., 1986; Boudin et al., 1993) or against 
severe malaria (Brasseur et al., 1990) has been reported. 
Evidence from field studies in Ghana (Dodoo et al., 2000), Senegal (Oeuvray et al., 2000) and 
East Asia (Soe et al., 2004) suggest that cytophilic antibodies are associated with a lower risk 
for subsequent clinical malaria episodes. These isotypes are also associated with the 
antibody-dependent cellular inhibition as discussed above. The importance of 
immunoglobulin isotypes in addition to the antigen specificity of the humoral response is 
underscored by studies that report an association between the levels of noncytophilic 
antibodies and clinical malaria incidence. IgG4 antibodies are preferentially induced after 
repeated exposure (Aalberse et al., 1983a; Aalberse et al., 1983b) and this isotype is 
associated with enhanced risk of infection and with a high risk of clinical malaria episodes 
(Aucan et al., 2000).  
The attitude towards the use of measuring growth inhibition as an immune correlate has 
changed over the past five years. Invasion or growth inhibitory (GIA) activity was 
considered a reliable predictor of vaccine efficacy and the results from these assays were 
used to down-select potential vaccine candidates. Initially, GIA activity was determined by 
using purified immunoglobulins from preclinical or clinical trials at high concentrations and 
from these studies, strong inhibition was frequently observed. However, the same vaccines 
that generated very “high” GIA activities in rabbits and other preclinical models failed to 
induce protection in naïve US individuals (Spring et al., 2009; Duncan et al., 2011). In residents 
from malaria-endemic areas, GIA activity is, however, a common factor associated with 
protection against clinical disease (Dent et al., 2008). In this study, malaria-infected participants 
were drug-cured and followed up until their next malaria infection. Participants whose sera 
exhibited higher growth inhibition prior to drug cure were protected for significantly longer 
periods of time than those participants whose antibodies mediated only low GIA activities. 
Moreover, an age-dependent effect was observed in that GIA activity inversely correlated with 
the age of study participants. Another confounding factor is the historical exposure of study 
participants as vaccine efficacy differs dramatically between individuals with no prior malaria 
history vs. residents from malaria-endemic areas. For example, an AMA-1 vaccine tested in US 
naïve study participants resulted in relatively high GIA activities, but the same vaccine failed 
to induce either GIA activity or protection as defined by time to the next malaria episode when 
given to individuals in Mali (Miura et al., 2011).  
Review of the scientific literature on blood stage malaria vaccines reveals no straightforward 
strategy for evaluating a successful blood stage vaccine. A variety of reasons may be 
responsible for the contradictory outcomes.  
• Differences in the transmission rates (intensity and stability) and the short lifespan of 
malaria specific antibodies can skew the measurements and conclusions. Therefore, 
directly comparing study results from different geographic regions that are not 
matched by transmission rates and seasons should be avoided. Transmission rates may 
have an impact on the clinical outcome of malaria episodes as well as on the induction 
of natural immunity. 
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• Differences in the kinetics of induction of natural immunity (mainly caused by high 
transmission rates) may influence the immune factors mediating protection.  
• Differences in the definitions of clinical malaria and study endpoints. In some settings, 
are the individuals with no signs of malaria truly protected or simply not exposed to 
the parasite? 
• The quality of plate antigens used for the ELISA: Proteins used for in vitro analyses may 
be of inferior quality due to misfolding or truncation. Recombinant proteins may not 
represent the native antigen structure. Moreover, for the analysis of MSP-1 specific 
immune responses induced by natural exposure to the parasite, most investigators have 
focused on the MSP-1p19 fragment rather than the MSP-1p42 protein, which is initially 
presented on the merozoite surface. 
• Mismatching of recombinant antigens and parasite phenotype: In many studies, the 
parasite variant prevalent in the study area is not matched with the recombinant 
protein used for the in vitro analysis (e.g., plate antigen for ELISA assay).  
• Differences in the age of study participants: concentrations of malaria-specific 
antibodies are age dependent and, therefore, only comparisons of study participants 
with similar ages are valid. 
• Lack of information about study participants’ conditions such as the use of bed nets, 
use of anti-malarial drugs or folk-medicine, co-infection with other parasites, bacteria 
and viruses.  
• Incompatibility in study design: in some cases study participants are pre-treated with 
anti-malarial drugs to clear parasites from the circulation prior to immunization while 
in other studies vaccines are administered while study participants have – in some cases 
significant numbers of- parasites in the blood. Therefore, it is inappropriate to compare 
vaccine potency and efficacy between such studies. 
4. Identification of antigens that are targeted by immune responses in 
immune individuals  
The merozoite consists of the merozoite surface coat, the micronemes, the rhoptries, 
apicoplast and a nucleus. From each of these components several antigens have been 
isolated and their immunological potential and biological function has been evaluated.  
4.1 Merozoite surface coat antigens 
Several antigens expressed on the merozoite surface coat have been evaluated as vaccine 
candidates. Highlighted in this section are the most frequently targeted of those antigens: 
- MSP-1: the properties and functions of this antigen will be discussed in detail in Section 
5 since this antigen represents a major blood stage vaccine candidate (Ockenhouse et al., 
2006; Ogutu et al., 2009). 
- MSP-2: immunization with the recombinant protein MSP-2 protects non-human 
primates and has yielded allele-specific reduced parasite density in field studies 
(Genton et al., 2002). Much of the development of MSP-2 as a vaccine in the field has 
been hampered by the fact that MSP-2 is an unstructured protein that tends to form 
amyloid fibrils in solution (Genton et al., 2003). Therefore, quality control of 
manufactured vaccines is difficult without a known structure or conformation-
dependent antibodies. 
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- MSP-3: this protein is non-covalently attached to the surface of the merozoite. This is 
different from MSP-1 and MSP-2, which are GPI-anchored proteins. Disruption of the 
MSP-3 gene is not lethal while genetic knockouts of MSP-1 and MSP-2 are. Similar to 
MSP-1, allelic dimorphism has been reported. MSP-3 specific antibodies found in sera 
from malaria-endemic areas are associated with protective immunity (Soe et al., 2004). 
MSP-3 based vaccines have been designed as long peptides representing the conserved 
C-terminus of the antigen (Druilhe et al., 2005; Sirima et al., 2007). Anti-parasite activity 
of MSP-3 specific antibodies was not evident unless monocytic cells were used in the 
assay (ADCI). 
- Glutamate-rich protein (GLURP): this antigen is not only expressed on the merozoite 
surface, but also on the liver stage parasite making it an attractive potential target for a 
multi-stage vaccine. The N-terminal region of the antigen is quite conserved and thus 
synthetic peptides representing the N-terminal non-repeat region have been tested in 
the clinic. Antibodies induced by these GLURP-peptides were able to inhibit parasite 
growth in the presence of monocytes indicating that - similar to MSP-3 - anti-GLURP 
antibodies act through ADCI (Hermsen et al., 2007). Several clinical studies have been 
conducted with GLURP alone (Hermsen et al., 2007) or in combination with MSP-3 
(Esen et al., 2009; Belard et al., 2011). 
4.2 Antigens within merozoite organelles 
Antigens found in the apical organelles of the merozoites such as the apical membrane 
antigen (AMA)-1 or the erythrocyte binding antigen (EBA-175 RII) have long been studied 
due to their immunogenicity or biological function. While the exact function of AMA-1 is 
unknown, EBA-175 has been better characterized. EBA-175 is found in the micronemes of 
the merozoite and is secreted by merozoites in order to bind to erythrocytes that are ready 
for invasion. This binding facilitates the attachment of merozoites to the coated erythrocytes 
in a strain-specific manner (Camus and Hadley, 1985). EBA-175 is a member of a family of 
binding proteins such as EBA-140, EBA-181, MAEBL; all of these antigens share a receptor 
binding domain (Region (R)-II). The analysis of sera from malaria-endemic areas for the 
presence of EBA-175 specific antibodies revealed some association with protection in 
children that have higher antibody titers (reviewed in (Fowkes et al., 2010)). Recently, an 
EBA-175 based vaccine yielded some clinical efficacy (El Sahly et al., 2010). 
AMA-1 is a highly polymorphic antigen generated in the rhoptries of the merozoites and it 
appears on the parasite’s surface just before invasion occurs. AMA-1 is highly immunogenic 
and anti-AMA-1 antibody responses are found in sera from individuals living in malaria-
endemic areas. Another promising feature of this antigen is the fact that AMA-1 is expressed 
on sporozoites and thus the antigen could act as a pre-erythrocytic as well as an erythrocytic 
vaccine. Analysis of AMA-1 specific antibodies in growth inhibition assays provided even 
more promise as the antibody activity is typically very high compared to other blood stage 
antigens. A clinical study in which volunteers were challenged by mosquito bite revealed 
that vaccination with AMA-1 was unable to provide sterile protection and only yielded a 
limited delay in the development of parasitemia in vaccinees compared to challenge control 
subjects (Spring et al., 2009). Characterization of the AMA-1 gene sequence revealed a fatal 
characteristic of this antigen which will likely preclude its use as a malaria vaccine in the 
field: well over 150 allelic variants of the antigen have been reported (Takala et al., 2009) and 
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humoral responses against AMA-1 indicate that immunity is allele-specific and therefore, an 
AMA-based vaccine would primarily provide strain-specific protection at best. Efforts are 
underway to develop AMA-1 vaccines that induce allele-cross-reactive responses to 
overcome this limitation (Remarque et al., 2008; Dutta et al., 2010). However, the success of 
any AMA-1 based malaria vaccines is also impeded by the fact that sera from malaria-
endemic areas appear to contain antibodies capable of blocking the activity of AMA-1 
specific antibodies (Miura et al., 2008). 
4.3 Antigens expressed on the surface of infected erythrocytes 
The access of antibodies to merozoite antigens is limited as merozoites quickly invade new 
erythrocytes. Antibodies have the ability to gain entry to into infected erythrocytes 
(Bergmann-Leitner et al., 2009), but cannot mediate ADCI and would act independently of 
phagocytic cells as described above. Therefore, efforts are underway to identify antigens on 
pRBC which are theoretically always accessible for binding by specific antibodies. The 
surface localization of the antigens indicates that they are crucial for sequestration of the 
pRBC in the placenta or post-capillary venules. This warrants their exploration as potential 
vaccine targets. The variant surface antigens (VSA) (reviewed in (Hviid, 2010)) have been 
shown to mediate sequestration of the parasite and immune responses towards these 
antigens confer protection in a strain-specific manner. One of the members, the P. falciparum 
erythrocyte membrane protein (PfEMP)-1, has been reported to be encoded by the var gene 
family and displays varying immunogenicity depending on the variant that is generated 
(Bull et al., 2005). One of these variants, var2csa is expressed by parasites that sequester in 
the placenta leading to severe malaria attacks in primagravid women often resulting in 
miscarriage and/or death of the mother (reviewed in (Beeson and Duffy, 2005)). This has led 
to efforts to develop vaccines that will be administered prior to or early in pregnancy (Avril 
et al., 2009). 
4.4 Multi-antigen responses: Reducing the risk for clinical infection or reducing 
parasite density 
The analysis of naturally acquired antibodies induced by the malaria parasite in an attempt 
to identify their antigen-specificity is challenging. Studies have frequently focused on a few 
select antigens, thus ignoring this complexity and the possibility of synergy in the response 
to multiple antigens. The complexity of these humoral responses was demonstrated using 
microarray assays in which 18 recombinant antigen fragments spanning various regions and 
alleles of four leading vaccine candidates (namely, MSP-1, MSP-2, MSP-3 and AMA-1) were 
tested (Gray et al., 2007). The results clearly demonstrate complex combinations of specific 
antibodies leading to an association with some form of protection. Reactivity to individual 
antigens did not correlate with protection, but combinations of antibodies to AMA-1 and 
allelic variants of MSP-2 were prevalent in individuals protected against clinical malaria. 
A field study in Senegal in which factors such as reappearance of parasites, asymptomatic 
carriage of parasites, time to first clinical episode, and incidence of clinical episodes were 
considered led to the observation that antibodies to NANP, MSP-1p19, PfEMP-3, PfEB200 
were associated with a lower risk for severe disease (Perraut et al., 2003). Another 
comprehensive study conducted in Senegal (305 children followed over 1 year) showed that 
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different mechanisms mediate protection: higher levels of IgG1 specific for GLURP and 
IgG3 for MSP-2 in children correlate with resistance to malaria and high-level parasitemia 
compared to malaria-susceptible children (Courtin et al., 2009). Higher anti-MSP-1 IgG1 
levels were associated with protection against high-density parasitemia. The study also 
evaluated the in vitro anti-parasite activity of the sera from these children and reported an 
age-dependent decline in the in vitro GIA activity of the sera. The GIA activity was 
dependent on anti-MSP-1, anti-AMA-1 and anti-MSP-2 specific antibody titers. 
A recent comprehensive meta-analysis of 33 clinical studies investigated the relationship 
between anti-merozoite antibodies and the incidence rate of malaria (Fowkes et al., 2010). 
The closest association between antibody titers and reduced risk was observed with IgG 
specific for the C-terminus of MSP-3 and MSP-1 (MSP-1p19). In contrast, antibodies directed 
to the N-terminus of MSP-1 and the presence of antibodies to MSP-2 was not significantly 
associated with protection. The analysis also revealed a positive association between 
reduced risk for infection and antibody titers against AMA-1 and GLURP-R0. 
5. MSP-1 and its role in immunity and infection 
Our laboratory has focused on the major merozoite surface protein -1 (MSP-1). This antigen 
was identified in immune complexes from merozoite lysates (gp195), which provided the 
rationale for developing vaccines against it (Lyon et al., 1997). MSP-1 is first produced as a 
195kD precursor that undergoes two successive proteolytic cleavage events (Blackman et al., 
1994). The second processing event occurs immediately before invasion, resulting in the 
cleavage of the p42 molecule into a p33 and a p19 fragment. The p19 fragment remains 
attached to the merozoite surface through a GPI anchor (Gerold et al., 1996) and is 
comprised of two epidermal growth factor (EGF)-like domains (Morgan et al., 1999), which 
may have a role in the invading complex. Serological studies have provided significant 
evidence suggesting that immune responses directed against the C-terminus of MSP-1 
(MSP-1p19 and MSP-1p42) are associated with immunity in preclinical models (Long et al., 
1994; Egan et al., 1999; Darko et al., 2005; Parkkinen et al., 2006). Moreover, protective 
immunity as defined by lower mortality and morbidity of individuals residing in endemic 
areas was also associated with MSP-1p19 (Egan et al., 1999; John et al., 2004). 
5.1 The role of MSP-1 in natural immunity 
Various biological factors influencing the function of MSP-1 specific antibodies have been 
reported in individuals with natural immunity: 
(1) The role of MSP-1 specific antibody titers, isotype and the association with protection 
and/or reduction in morbidity: 
A meta-analysis of 33 clinical studies revealed that the presence of MSP-1p19 specific 
antibodies is associated with a lower incidence rate of malaria (Fowkes et al., 2010). 
Moreover, high levels of anti-PfMSP-1p19 immunoglobulin G were associated with reduced 
malaria in an age-adjusted multivariate analysis (Perraut et al., 2005). In contrast, other 
reports failed to show any associations between MSP-1p19 (MSP-1) Abs and clinical 
outcome (Dodoo et al., 1999; Nebie et al., 2008). At this point we can only speculate about 
the cause of this discrepancy. As outlined above, the differences in the methodology and/or 
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choice of plate antigen may be responsible for some of these issues. It is, however, 
interesting to note that full length MSP-1p42 was only used in one study as the plate antigen 
and this study reported a reduced risk of malaria (Al-Yaman et al., 1996).  
(2) The role of antibody isotype and functional activity against the parasite: 
Longitudinal studies have demonstrated an association between the IgM and IgG responses 
to MSP-1p19 and the degree of clinical disease and anemia in infants and pregnant women 
(Branch et al., 1998). Similarly, high antibody levels of MSP-1 specific IgG1 were associated 
with reduced morbidity (Riley et al., 1992; Al-Yaman et al., 1996) with protection against 
high-level parasitemia (Fowkes et al., 2010) and clinical disease (Egan et al., 1996; Cavanagh 
et al., 2004; Soe et al., 2004). 
(3) The role of fine specificity of antibodies and association with protection:  
IgG derived from sera obtained from Kenyan residents were tested for their impact on 
parasite viability and growth. The results demonstrated that the invasion inhibitory 
antibodies were specific for the C-terminal MSP-1p19 (John et al., 2004). Overall, there was a 
lack of association of total IgG or IgG subclass Abs to MSP-1p19 measured by ELISA with 
either invasion-inhibitory activity or protection against infection. In contrast, a study 
analyzing sera from children in West Africa (Sierra Leone and Gambia) demonstrated a 
strong association between antibody titers to the C-terminus of MSP-1 (MSP-1p19) and 
protection against clinical malaria and high level parasitemia (Egan et al., 1996). Thus, the 
fine specificity (i.e., epitope specificity) of the MSP-1 specific antibodies appears to be 
important and testing only for antibody titers to the total molecule or a fragment may result 
in the loss of an association with a clinical response (Corran et al., 2004; Okech et al., 2004). 
The C-terminus of the MSP-1 is comprised of two EGF-like domains and depending on 
which of the domains the antibodies recognize results in either growth inhibition or no 
functional activity against the parasite (Chappel et al., 1994; Darko et al., 2005). 
5.2 Efficacy of MSP-1 based vaccines in naïve and malaria-exposed individuals 
Several clinical trials have been conducted testing either MSP-1p42 or MSP-1p19 as vaccine 
candidates. The objective of using the larger subunit, MSP-1p42, was to ensure that potential 
helper epitopes, which can induce antibodies are present in the immunogen. Moreover, the 
N-terminus p33 portion of the molecule contains most of the known T cell epitopes. The 
nature of the C-terminus, i.e., due to several disulfide bridges associated with the EGF-like 
domains, renders the structure rigid and thus resistant to processing by antigen presenting 
cells, and therefore does not contain any dominant T cell epitopes. Thus, using the full 
length p42 fragment, which is expressed on pRBC starting at the trophozoite stage, would 
allow antibodies to bind to the parasites even inside the pRBC thereby potentially 
preventing the rupture of schizonts. This fact motivated two institutions (National Institute 
of Health (NIH) and Walter Reed Army Institute of Research (WRAIR)) to proceed with two 
independent MSP-1p42 based vaccines. At the NIH, a mixture of MSP-1p42 (FVO) and MSP-
1p42 (3D7) was adjuvanted with Alhydrogel together with or without the addition of 
CpG7909 (Ellis et al., 2010) while the WRAIR vaccine consisted of single-allele vaccines, 
MSP-1p42 (3D7) (Ockenhouse et al., 2006) or MSP-1p42 (FVO) (Spring et al., manuscript in 
preparation), adjuvanted with GSK‘s adjuvant system, AS02A or AS01B, respectively. Both 
were tested in US naïve individuals. All studies reported good immunogenicity and - in the 
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case of the single allele vaccine - moderate growth inhibitory activity was induced. The 
MSP-1p42 vaccines generated at WRAIR underwent further clinical evaluation in Phase Ib 
studies conducted in Kenya (Stoute et al., 2007) and Mali (Thera et al., 2006), where adults 
were immunized with the MSP-1p42 (3D7) adjuvanted in AS02A. In Kenya, although pre-
existing MSP-1p42 antibody titers in the participants were high, they could be boosted by the 
vaccine. In addition, Phase Ib (Withers et al., 2006) and Phase IIb (Ogutu et al., 2009) studies 
were conducted in Kenyan children (1-4 years old) using the same vaccine formulation. 
Results from this study indicated that younger children mounted stronger vaccine responses 
in terms of the magnitude of the antibody response. Sera from the Phase IIb study displayed 
strong growth inhibitory activity against the heterologous FVO parasites indicating that the 
predominant strain circulating at the time of natural exposure was different from the vaccine 
strain 3D7 (Angov et al., manuscript in preparation). Growth inhibitory activity to the 3D7 
parasites was only observed in a small proportion of the study population with no significant 
difference between the rabies control group (Rabipur) and the malaria vaccine group. Some 
3D7 specific GIA activity was reversible by antigen add-back confirming that some of the 
activity in the sera was due to MSP-1 specific antibodies. The major conclusion from this trial 
was that although the vaccine was safe and immunogenic, in the context of the heterologous 
exposure, the vaccine did not induce sufficiently cross-reactive responses. Future studies 
should include MSP-1p42 allele(s) that are better matched to the dominant circulating 
parasites. Another important consideration is to clear parasitemia in the study participants 
prior to and during the course of the vaccination. The presence of parasites during vaccination 
could lead to competitive immune responses thus curtailing the vaccine’s potential. 
Some vaccine approaches have focused on the MSP-1p19 fragment rather than the full-
length MSP-1p42 since this region of the molecule contains the highly conserved 
functionally important B cell dominant epitopes. In one particular construct, helper T cell 
epitopes from tetanus toxoid were used to generate a chimeric P30P2-MSP-1p19 protein 
(Keitel et al., 1999). Others approached the lack of T cell help by generating a chimeric 
AMA-1/MSP-1p19 vaccine, which was tested in a Phase Ia trial (Malkin et al., 2008). This 
vaccine induced antibodies to both antigens; however the antibodies reacted primarily to 
the recombinant antigens by ELISA, less well by immunofluorescence assay (IFA) on whole 
parasites, and showed no activity in growth inhibition assays.  
Therefore, with regards to further characterizing of MSP-1-based vaccine approaches, there is 
a need for reliable readout preclinical methods to enable prediction of protection and to 
facilitate the down-selection of vaccine candidates. One such attempt was the development of 
a transgenic rodent malaria parasite (P. berghei) expressing the P. falciparum MSP-1p19 
transgene (De Koning-Ward et al., 2003). These parasites may be useful in the down-selection 
of vaccine candidates by either immunization strategies in the murine model (which does not 
necessarily address immunogenicity in humans) or passive transfer strategies to characterize 
the immune potential of antibodies induced in vaccinated individuals. Moreover, a recent 
report suggests that some anti-MSP-1 specific antibodies may mediate ADCI. Due to the 
incomplete compatibility between human Abs and murine Fc receptors, current mouse models 
are unable to use this pathway and may lead to false negative results. There are some 
experimental alternatives such as transgenic mice that express one of the human Fc receptors 
(CD32 or CD64) or humanized mice. Humanization refers to irradiated mice that have been 
reconstituted with human leukocytes (Badell et al., 2000; Pleass et al., 2003) or hematopoietic 
stem cells which leads to the production of an array of human blood cells in the mice. 
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5.3 Biological effect of MSP-1 specific antibodies on parasite growth and function 
Characterizing immune responses induced by MSP-1 vaccines revealed that several factors 
impact the immunogenicity and functional activity of the induced antibodies (vaccine 
platforms will be discussed in detail in Section 6): (1) the expression system used for the 
production of the recombinant protein (i.e., E. coli, baculovirus, or yeast) (Arnot et al., 2008; 
Reed et al., 2009), (2) the amino-acid sequence used for vaccine development (i.e. full length 
gp195, MSP-1p42 or MSP-1p19) (Stowers et al., 2001; Woehlbier et al., 2006) and (3) the 
vaccine platform used to deliver the MSP vaccine (i.e, recombinant protein, recombinant 
viral vectors or DNA vaccines).  
Our laboratory has intensively studied the anti-parasite effects induced by MSP-1p42 
specific antibodies. Early observations indicated that MSP-1 specific antibodies impacted the 
various parasite strains differently depending on their classification as MAD20 or 
Wellcome/K1-like. These two alleles differ markedly in their p33 fragments while only by 
four amino acids (E-TSR vs. Q-KNG, respectively) in the p19 portion of the molecule. To this 
end, MSP-1 specific antibodies were able to significantly delay the intra-erythrocytic 
development of the 3D7, but not the FVO parasite clone (Bergmann-Leitner et al. 2009). In 
the case of FVO parasites, anti-MSP-1p42 antibodies prevented schizont rupturing by 
stalling or arresting intra-erythrocytic parasite development likely through direct 
interactions with intra-erythrocytic parasites within the parasitophorous vacuole, which is 
putatively connected to the surface of the pRBC by the parasitophorous duct. This duct 
gives antibodies, but not larger immune components access to the parasite inside the 
vacuole (Bergmann-Leitner et al., 2009). In contrast, the same antisera tested on the 3D7 
parasite clone were unable to interfere with the release of the merozoites. These antibodies 
were still able to agglutinate merozoites and interfere with invasion. We expanded our 
analysis to the parasite clone CAMP/FUP that has a p33 and a p19 EGF-like domain 1 
identical to the sequence of the 3D7 parasite clone, and an EGF-like domain 2 identical to the 
FVO parasite clone. We observed the same response pattern as reported for the FVO 
parasite indicating that antibodies within the EGF-like domain might be responsible for 
stalling the rupture of the schizonts. In contrast, no significant growth inhibition was 
observed following successful invasion indicating that EGF-like domain 1 specific 
antibodies may be mediating this particular biological effect. To test this working 
hypothesis, the activity of affinity purified antibodies specific to the entire p19 or each of the 
EGF-like domains were compared to the source material (antibodies induced by 
immunization with the MSP-1p42 vaccine representing either the FVO or the 3D7 allele). We 
concluded that only antibodies that bound to regions within the p42 or to the p19 subunit, 
but not the EGF-like domain 1 or 2 subunits, displayed growth inhibitory activities. This 
was surprising given previous observations suggesting that responses directed to the p19 
were associated with reduced parasite density or clinical disease (see above). However, the 
proper folding of the recombinant fragments used, which represent the two EGF-like 
domains has not yet been confirmed. This result may indicate that protective epitopes may 
depend on proper tertiary structure of the molecule. In support of this theory, it has been 
reported that inhibitory anti-MSP-1 specific antibodies map to epitopes formed through the 
“properly” folded p19 subunit and not to its sub-domains (McBride and Heidrich, 1987; 
Uthaipibull et al., 2001). 
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One biological function known to be displayed by some MSP-1 specific antibodies is the 
inhibition of the secondary processing of the MSP-1 molecule into the p33 and the p19 
portion (Blackman et al., 1994). This activity was found in sera from individuals with 
acquired natural immunity (Patino et al., 1997). In this assay, merozoites are prepared from 
synchronized blood stage cultures and their ability to process MSP-1p42 into p33 and p19 in 
the presence or absence of immune antibodies is evaluated. This method is qualitative at 
best and due to its nature not designed for high-throughput testing. Thus, very few 
laboratories use the technique for the evaluation of functional activity in immune sera. 
6. Future direction 
The current body of literature clearly supports the development of a blood stage vaccine. 
Although such a vaccine would not prevent infection, it can reduce morbidity and mortality 
associated with malaria infection and therefore such a vaccine would save the lives of many 
residents of malaria-endemic areas. The experience and knowledge gained from these 
studies should be used to rationally design new vaccine formulations and future clinical 
trials. Factors that need to be considered for their success are: 
(1) Vaccine platform. Most erythrocytic vaccines tested so far are based on recombinant, 
soluble proteins. When using recombinant proteins it is paramount to assure proper, thus 
native-like, protein folding. Sera from malaria-endemic areas are a useful tool to establish 
the degree of cross-reactivity between the recombinant vaccine and the “native” antigen. 
Alternative vaccine platforms to those primarily described here, soluble proteins plus 
adjuvant, are particle-based approaches. When using this approach it is important to assure 
proper orientation of the protein on the particle. Some proteins that are inherently 
unstructured such as MSP-2 could benefit from particle formation because the particle 
provides a stabilizing scaffold. Moreover, the distance between the epitopes and the density 
may be crucial in order to induce proper immune responses. Such particle presentation 
could be achieved by using either recombinantly expressed antigen on whole-killed bacteria 
or viruses. For example, mouse studies using recombinant adenovirus encoding MSP-1 
demonstrated “protection” (defined by the authors as delayed and lower parasitemia) 
(Draper et al., 2009). 
(2) Development of preclinical and clinical models that better predict human anti-malarial responses. 
When using preclinical animal models, the parasite growth kinetic is frequently different 
between those Plasmodium species that are suitable for the respective animal model and P. 
falciparum thus failing to simulate the clinical situation. Testing vaccine candidates in 
animals can be challenging when testing P. falciparum antigens: except for one confirmed 
antigen, PfCelTOS, (Bergmann-Leitner et al., 2010), malaria antigens are relatively species-
specific, i.e., immunization with P. falciparum antigens does not confer protection against a 
heterologous Plasmodium species. Thus, investigators often make their decisions based solely 
on immunogenicity in the animal model (cellular and/or humoral responses notionally 
thought to be important). Alternatively, investigators have searched for orthologs of the P. 
falciparum antigen in the respective Plasmodium species relevant for their preclinical model to 
conduct immunization and challenge studies. A caveat of this approach is that the ortholog 
may have a different function than the P. falciparum antigen in human malaria or there 
simply may not be a valid ortholog (e.g. P. falciparum LSA-1 does not have an ortholog in 
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rodent Plasmodia). Another important consideration for the establishment of relevant models 
of human malaria is the immunization and challenge routes. Challenge routes should take 
into consideration the natural inoculation route. Our work with pre-erythrocytic antigens 
has shown that vaccine efficacy can vary significantly if the challenge route is changed 
(intravenous vs. mosquito bite) and thus the efficacy of a vaccine could be over- or 
underestimated if an artificial challenge method is used (Leitner et al., 2010) which may 
bypass vaccine-induced effector mechanisms (Vanderberg et al., 2007). For erythrocytic 
antigens this has been an issue as well because - until recently - it was ethically 
inconceivable to challenge human volunteers with malaria-infected blood due to the risk of 
transmitting life threatening blood borne diseases. However, extensive testing of the blood 
source used for the challenge has allowed a limited challenge study with the understanding 
that significant improvements are needed before blood challenges can be performed 
routinely similar to the mosquito bite challenges (Moorthy et al., 2009). A final issue to 
consider is that blood stage challenge in humans may not fully predict the situation where 
an individual receives a blood stage vaccine followed by mosquito bite challenge, as the 
vaccine-induced immune responses may be edited (i.e., altered) by the sporozoite and the 
liver-stage infection.  
(3) Improving surrogate readout assays to down-select vaccine candidates. At this time, different 
assays are being used as surrogate markers for down-selecting vaccine candidates. Without 
an immune correlate of protection, the predictive value of these readout methods remains 
questionable. Therefore, identifying immune correlates for the various target antigens is 
necessary to ‘validate’ the readout methods and allow their use for rational down-selection 
of vaccine candidates 
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